SLU PP 332

SLU-PP-332 is a potent, non-selective agonist of estrogen-related receptors (ERRs), primarily targeting ERRα with an EC50 of 98 nM, modulating mitochondrial function and energy metabolism. Known as an “exercise mimetic,” this synthetic small molecule activates metabolic pathways akin to those triggered by endurance training, enhancing fat oxidation, glucose utilization, thermogenesis, and cellular respiration without physical exertion. In preclinical studies, it has shown promise in counteracting metabolic syndrome, promoting weight loss, improving mitochondrial biogenesis, and potentially aiding conditions like obesity, type 2 diabetes, and fatty liver disease by boosting ERR-driven gene expression such as PGC-1α and PDK4.

Buy SLU-PP-332 Peptide For Research at Peptides Please

Purchase high-purity SLU-PP-332 peptide, a potent ERRα agonist mimicking exercise effects by boosting mitochondrial biogenesis, fat oxidation, and energy expenditure, exclusively for research purposes at Peptides Please—your trusted source for research-grade compounds with rigorous quality testing, proper lyophilized storage recommendations, and competitive pricing for biomedical studies on metabolic health and performance enhancement.

What Is SLU PP 332?

SLU PP 332, a potent and selective estrogen-related receptor (ERR) agonist, has emerged as a promising compound in preclinical studies targeting metabolic disorders, particularly in models of obesity. In obese mice, administration of SLU PP 332 significantly reduced body weight and decreased fat mass accumulation by enhancing fatty acid oxidation and improving overall fatty acid metabolism. These effects stem from its activation of ERRα, a key regulator of energy homeostasis, which promotes mitochondrial function and lipid utilization in peripheral tissues.

Beyond fat loss, SLU PP 332 demonstrates benefits for skeletal muscle, increasing muscle mass and enhancing muscle function without relying on traditional exercise stimuli. In obese mice, it upregulated genes involved in oxidative metabolism within skeletal muscle, leading to improved endurance and strength. This dual action on fat reduction and muscle preservation positions SLU PP 332 as a potential therapeutic for combating obesity-related sarcopenia, offering a novel approach to body composition optimization.

SLU PP 332 Peptide Mechanism of Action

SLU‑PP‑332 is an “exercise‑mimetic” ERR agonist whose mechanism centers on activating estrogen‑related receptors—primarily ERRα—in metabolically active tissues, driving a transcriptional program that increases mitochondrial biogenesis, oxidative metabolism, and fat utilization.

Core receptor‑level mechanism

• SLU‑PP‑332 is a potent agonist of the estrogen‑related receptor family (ERRα > other ERRs), binding the ligand‑binding domain and stabilizing the receptor’s active conformation.
• Activated ERRα recruits co‑activators, especially PGC‑1α, forming a transcriptional complex that binds estrogen‑related response elements (ERREs) on DNA.
• This complex upregulates large sets of exercise‑responsive genes involved in mitochondrial function, oxidative phosphorylation, and substrate handling.

Downstream molecular effects

• Mitochondrial biogenesis and function: Increased PGC‑1α and mitochondrial genes promote higher mitochondrial content and oxidative capacity in skeletal muscle and other high‑demand tissues.
• Substrate utilization: Upregulation of fatty‑acid oxidation enzymes and uncoupling proteins shifts metabolism toward enhanced fat oxidation and thermogenesis, raising energy expenditure.
• Glucose handling: Elevated GLUT4 and related transporters improve glucose uptake and insulin sensitivity in metabolically active tissues.

Tissue‑level and functional outcomes (preclinical)

• In rodent models, SLU‑PP‑332 behaves as an exercise mimetic: promoting a more oxidative muscle phenotype, improving endurance, and counteracting features of metabolic syndrome, including diet‑induced obesity.
• It increases whole‑body energy expenditure and restrains weight gain without reducing appetite, consistent with a primary effect on mitochondrial efficiency and substrate oxidation rather than caloric intake.

Simple “structure → function” summary

• Structural features: Short to medium‑length peptide/small‑molecule‑like scaffold with side‑chain architecture tuned for high‑affinity ERRα binding and conformational stabilization under physiological conditions.
• Functional consequence: Because this scaffold selectively engages ERRα and enhances its interaction with co‑activators, the compound effectively reprograms cellular energy metabolism toward an exercise‑like, oxidative, high‑mitochondrial state, explaining its endurance and fat‑loss effects in preclinical research.

SLU-PP-332 Benefits

SLU-PP-332 shows promising preclinical benefits as an exercise-mimetic compound, primarily enhancing metabolic function, endurance, and fat metabolism in rodent models.

Metabolic and fat loss benefits

• Increases basal energy expenditure and fatty acid oxidation, leading to reduced fat gain and adiposity on high-fat diets without altering appetite.
• Improves glucose tolerance, insulin sensitivity, and reduces liver fat accumulation in models of metabolic syndrome.
• Enhances mitochondrial biogenesis and oxidative capacity across muscle, liver, and adipose tissues.

Performance and muscle benefits

• Boosts running endurance, VO2 max, and shifts muscle toward oxidative, fatigue-resistant fibers similar to aerobic training.
• Increases mitochondrial content, capillary density, and respiratory efficiency in skeletal muscle.

Cardioprotective and organ benefits

• Improves cardiac contractility, reduces cardiomyocyte death, and limits fibrosis in heart failure models.
• Shows potential protection against age-related metabolic decline, kidney issues, and other organ stress via metabolic reprogramming.

SLU-PP-332 Side Effects

SLU-PP-332 is an experimental, pre-clinical compound designed to mimic exercise by boosting metabolism and fat burning. While studies on mice show no severe side effects, potential (yet unconfirmed) risks in humans may include mild injection site irritation, headache, fatigue, and hormonal or cardiovascular effects due to its mechanism of action.

• Minimal Acute Effects: In initial mouse models, the compound did not cause adverse effects on food intake or appetite.
• Reported Minor Reactions: Some studies note possible minor side effects such as headache, fatigue, or mild injection site irritation.

• Cardiovascular and Hormonal Concerns: As a potent activator of estrogen-related receptors (ERRα), it carries unverified risks like cardiac hypertrophy (thickening of the heart muscle) and hormonal imbalances.
• Metabolic Shifts: The compound alters fat processing, potentially leading to changes in lipid profiles.

SLU-PP-332 Clinical Trials

SLU-PP-332, a potent estrogen-related receptor (ERR) agonist, is advancing toward clinical trials for metabolic diseases, building on promising preclinical data showing its ability to boost increased energy expenditure and enhance metabolic efficiency in diet-induced obese models; as an experimental therapeutic, it activates ERRs to improve cellular respiration and whole body metabolism, positioning it as a potential treatment for obesity and related conditions by mimicking the effects of physical exercise without actual activity.

SLU-PP-332 Human Trials

Human trials for SLU-PP-332 in metabolic diseases are anticipated soon, following robust preclinical validation in skeletal muscle cell lines and animal models where it drove increased energy expenditure, supported mitochondrial health, and optimized whole body metabolism and metabolic efficiency; this ERR agonist enhances cellular respiration akin to physical exercise, offering hope for diet-induced obese patients through experimental therapeutics that promote fat loss and energy utilization without traditional interventions.

SLU PP 332 Price

Unlock peak performance in your peptide research with SLU-PP-332 (5mg) at just $110.00—your gateway to cutting-edge investigation of this potent selective androgen receptor modulator (SARM) mimetic, designed to drive muscle hypertrophy, accelerate fat metabolism, and enhance endurance without the hormonal disruptions of traditional steroids. Sourced from top-tier labs for unmatched purity and stability, this research-grade vial at PeptidesPlease empowers precise dosing in bodybuilding, recovery, and metabolic protocols, making it an essential for scientists tracking next-gen therapies. Stock up now and elevate your experiments—limited availability at this competitive price.

Research SLU-PP-332 for Sale at PeptidesPlease

SLU-PP-332 is a potent pan-ERR agonist (EC50 values: 98 nM for ERRα, 230 nM for ERRβ, 430 nM for ERRγ) that activates estrogen-related receptors to enhance mitochondrial biogenesis, oxidative metabolism, fatty acid oxidation, and energy expenditure, mimicking exercise effects in skeletal muscle, cardiac tissue, and metabolic models while improving insulin sensitivity and reducing fat mass in preclinical studies. For research-grade SLU-PP-332 purchase, PeptidesPlease offers high-purity (≥99%) peptides, proteins, and amino acid derivatives synthesized via advanced solid-phase/solution-phase methods with third-party verification, strict quality controls, and stability packaging exclusively for scientific laboratory use—not human consumption. Researchers like you in biochemistry and peptide studies can explore their catalog for compatible metabolic research compounds, ensuring compliance with research-only protocols.

Frequently Asked Questions

What is SLU-PP-332 used for?

SLU-PP-332 is a synthetic pan-ERR agonist (primarily targeting ERRα) researched for mimicking exercise effects, such as increasing energy expenditure, fatty acid oxidation, mitochondrial function, and exercise endurance in preclinical models. It shows potential in metabolic disorders, muscle enhancement, and reducing fat mass accumulation.

What are the side effects of SLU-PP-332?

Preclinical animal studies report no severe toxicity to liver, kidney, or heart, with mild anecdotal reports of anxiety, dizziness, or panic-like symptoms in self-experimenters. Human safety data is lacking due to no clinical trials yet.

What is another name for SLU-PP-332?

Alternative names include 4-Hydroxy-N’-(naphthalen-2-ylmethylene)benzohydrazide and (E)-4-Hydroxy-N’-(naphthalen-2-ylmethylene)benzohydrazide.

What is the shelf life of SLU-PP-332?

Powder form lasts up to 2 years at -20°C or 3 months refrigerated (2-8°C); reconstituted solutions are stable for 4-6 weeks at 2-8°C or up to 90 days.

Is SLU-PP-332 good for kidneys?

Preclinical research indicates potential kidney protection by reducing albuminuria, improving podocyte function, decreasing fibrosis, and reversing age-related mitochondrial dysfunction and inflammation.

How much is SLU-PP-332?

SLU-PP-332 (5mg) from PeptidesPlease costs $110.

What are the long-term effects of SLU-PP-332?

Limited data from short-term mouse studies (e.g., 15 days) show positive muscle physiology changes like increased oxidative activity, but human long-term effects and safety are unknown.

What are the benefits of SLU-PP-332?

Benefits in research include enhanced mitochondrial respiration, oxidative muscle fibers, exercise endurance, fat loss, metabolic improvements, and potential protection against heart failure or kidney decline.

What is the chemical formula for SLU-PP-332?

The molecular formula is C18H14N2O2, with a molecular weight of 290.32 g/mol.

Where can I buy SLU-PP-332?

SLU-PP-332 for research purposes is available from PeptidesPlease. They offer SLU-PP-332 (5mg) for $110.

Who developed SLU-PP-332?

SLU-PP-332 was developed by a team of researchers led by Thomas P. Burris at the Center for Clinical Pharmacology, Washington University School of Medicine, and St. Louis College of Pharmacy in St. Louis, Missouri.

Summary

In summary, SLU-PP-332 stands out as a potent, non-selective agonist of estrogen-related receptors (ERRs), particularly ERRα (EC50 98 nM), mimicking exercise effects by boosting mitochondrial biogenesis, fat oxidation, and energy expenditure in metabolically active tissues like skeletal muscle, liver, and heart. Preclinical studies in obese mouse models demonstrate its ability to reduce fat mass by 12% without altering food intake or lean mass, improve glucose tolerance, reverse hepatic steatosis, and enhance endurance capacity, positioning it as a promising exercise mimetic for obesity, metabolic syndrome, and performance optimization. While its safety profile appears favorable in early research with no major side effects reported, further human trials are essential to validate efficacy, dosing, and long-term metabolic benefits for therapeutic applications in weight management and anti-aging.